EPHA2 and familial pancreatic carcinoma: When comparing the OS obtained from patients under standard regimens of pancreatic cancer chemotherapy with GnP and mFFX, the MST among EphA2-NF–low cases was approximately two times longer than that of EphA2-NF–high cases treated with GnP.